C21 has a strong impact on several markers in an in vitro study for pulmonary fibrosis
A BioMAP® report comparing Vicore Pharma’s drug candidate C21 to two approved drugs for IPF shows strong and competitive results. The test was performed by DiscoverX, an American contract research organisation with a proprietary assay for analysing antifibrotic properties for drug candidates, i.e. the BioMAP® system. The objective of the BioMAP® report was to benchmark Vicore Pharma’s drug candidate C21 to two Idiopatic pulmonary fibrosis (IPF) approved drugs with documented antifibrotic properties in a panel for a large amount of inflammation and fibrosis biomarkers expressed by